Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
73 hedge funds and large institutions have $19.2M invested in Aevi Genomic Medicine Inc in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 9 closing their positions.
399% more call options, than puts
Call options by funds: $2.74M | Put options by funds: $549K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
0% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 21
4% less funds holding
Funds holding: 76 → 73 (-3)
78% less capital invested
Capital invested by funds: $88.1M → $19.2M (-$68.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.13M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.34M |
| 3 |
Goldman Sachs
New York
|
+$880K |
| 4 |
2L
22NW LP
Seattle,
Washington
|
+$701K |
| 5 |
RFCA
R&F Capital Advisors
New York
|
+$381K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$15.2M |
| 2 |
Jennison Associates
New York
|
-$8.91M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.52M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.94M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.95M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
76
Credit Suisse
Zurich,
Switzerland
| – | -$71K | -13,578 | Closed |
|
|
TRCT
77
Tower Research Capital (TRC)
New York
| – | -$20K | -3,870 | Closed |
|
78
Citigroup
New York
| – | -$4.82K | -1,065 | -96% |
|
79
Simplex Trading
Chicago,
Illinois
| – | -$1.85K | -408 | -58% |
|
80
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1K | -200 | Closed |
|
|
CG
81
Cutler Group
San Francisco,
California
| – | +$127 | +28 | New |
|
82
Barclays
London,
United Kingdom
| – | +$1.03K | +227 | +273% |
|
GNMX Hedge Fund Activity: Q1 2017 in Review
73 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2017, worth a combined $19.2M — down 78% from $88.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GNMX positions and 9 closed out — a net gain of 1 holder — while 21 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $9.13M. The largest seller was Broadfin Capital, exiting entirely with an estimated $15.2M sold.
- 73 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2017, down from 76 in Q4 2016.
- Funds reported $19.2M of Aevi Genomic Medicine Inc stock for Q1 2017, down 78% quarter-over-quarter.
- 10 funds opened new Aevi Genomic Medicine Inc positions in Q1 2017 and 9 closed out, a net change of +1 holder.
- The largest Aevi Genomic Medicine Inc buyer in Q1 2017 was BlackRock, an estimated $9.13M added.
- The largest Aevi Genomic Medicine Inc seller in Q1 2017 was Broadfin Capital, an estimated $15.2M sold.
Based on aggregated 13F filings for Q1 2017.